Jeffrey S. Parkin

Array ( [id] => 5290431 [patent_doc_number] => 20090023161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-01-22 [patent_title] => 'STRUCTURAL BASIS FOR TARGETING HIV-1 GAG PROTEINS TO THE PLASMA MEMBRANE FOR VIRUS ASSEMBLY' [patent_app_type] => utility [patent_app_number] => 12/175809 [patent_app_country] => US [patent_app_date] => 2008-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 11716 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0023/20090023161.pdf [firstpage_image] =>[orig_patent_app_number] => 12175809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5360533 [patent_doc_number] => 20090035327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-02-05 [patent_title] => 'Antibody Gene Transfer and Recombinant AAV Therefor' [patent_app_type] => utility [patent_app_number] => 12/145873 [patent_app_country] => US [patent_app_date] => 2008-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10097 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0035/20090035327.pdf [firstpage_image] =>[orig_patent_app_number] => 12145873 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5271005 [patent_doc_number] => 20090074781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-03-19 [patent_title] => 'Dengue virus peptide vaccine and methods of preparing and using the same' [patent_app_type] => utility [patent_app_number] => 12/156908 [patent_app_country] => US [patent_app_date] => 2008-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 9633 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0074/20090074781.pdf [firstpage_image] =>[orig_patent_app_number] => 12156908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5490047 [patent_doc_number] => 20090291118 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-11-26 [patent_title] => 'UNIVERSAL BARRIER TO PREVENT INFECTIONS FROM HUMAN IMMUNODEFICIENCY VIRUS' [patent_app_type] => utility [patent_app_number] => 12/126901 [patent_app_country] => US [patent_app_date] => 2008-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6100 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0291/20090291118.pdf [firstpage_image] =>[orig_patent_app_number] => 12126901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9046999 [patent_doc_number] => 08541553 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-09-24 [patent_title] => 'Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein' [patent_app_type] => utility [patent_app_number] => 12/601780 [patent_app_country] => US [patent_app_date] => 2008-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7418 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12601780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5429067 [patent_doc_number] => 20090088377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-04-02 [patent_title] => 'CYSTEIC ACID DERIVATIVES OF ANTI-VIRAL PEPTIDES' [patent_app_type] => utility [patent_app_number] => 12/122627 [patent_app_country] => US [patent_app_date] => 2008-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 29765 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0088/20090088377.pdf [firstpage_image] =>[orig_patent_app_number] => 12122627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4718664 [patent_doc_number] => 20080241186 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-10-02 [patent_title] => 'NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION' [patent_app_type] => utility [patent_app_number] => 12/122330 [patent_app_country] => US [patent_app_date] => 2008-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 11978 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0241/20080241186.pdf [firstpage_image] =>[orig_patent_app_number] => 12122330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5585027 [patent_doc_number] => 20090104229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-04-23 [patent_title] => 'NOVEL USE' [patent_app_type] => utility [patent_app_number] => 12/117205 [patent_app_country] => US [patent_app_date] => 2008-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 13213 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0104/20090104229.pdf [firstpage_image] =>[orig_patent_app_number] => 12117205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6627248 [patent_doc_number] => 20100172937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-08 [patent_title] => 'ENVELOPED VIRUS NEUTRALIZING COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 12/598702 [patent_app_country] => US [patent_app_date] => 2008-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 9042 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0172/20100172937.pdf [firstpage_image] =>[orig_patent_app_number] => 12598702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9626006 [patent_doc_number] => 08795682 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-08-05 [patent_title] => 'Virus-like particles comprising chimeric human immunodeficiency virus (HIV)/mouse mammary tumor virus (MMTV) envelopes' [patent_app_type] => utility [patent_app_number] => 12/598271 [patent_app_country] => US [patent_app_date] => 2008-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 27 [patent_no_of_words] => 17934 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12598271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6249442 [patent_doc_number] => 20100137415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-03 [patent_title] => 'VECTOR FOR GENE THERAPY' [patent_app_type] => utility [patent_app_number] => 12/596744 [patent_app_country] => US [patent_app_date] => 2008-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10904 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0137/20100137415.pdf [firstpage_image] =>[orig_patent_app_number] => 12596744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9868859 [patent_doc_number] => 08956627 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-17 [patent_title] => 'Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates' [patent_app_type] => utility [patent_app_number] => 12/450779 [patent_app_country] => US [patent_app_date] => 2008-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 46 [patent_no_of_words] => 11006 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12450779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6431175 [patent_doc_number] => 20100143377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-10 [patent_title] => 'PRODUCTS FOR PROPHYLAXIS AND/OR TREATMENT OF VIRAL DISEASES AND METHODS OF MAKING AND USING SAME' [patent_app_type] => utility [patent_app_number] => 12/595545 [patent_app_country] => US [patent_app_date] => 2008-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15151 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0143/20100143377.pdf [firstpage_image] =>[orig_patent_app_number] => 12595545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6380473 [patent_doc_number] => 20100316672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-16 [patent_title] => 'VACCINE' [patent_app_type] => utility [patent_app_number] => 12/450774 [patent_app_country] => US [patent_app_date] => 2008-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 2906 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0316/20100316672.pdf [firstpage_image] =>[orig_patent_app_number] => 12450774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7997571 [patent_doc_number] => 08080633 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-12-20 [patent_title] => 'Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides' [patent_app_type] => utility [patent_app_number] => 12/098094 [patent_app_country] => US [patent_app_date] => 2008-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 44 [patent_no_of_words] => 15152 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/080/08080633.pdf [firstpage_image] =>[orig_patent_app_number] => 12098094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6441876 [patent_doc_number] => 20100104596 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-29 [patent_title] => 'ACUTTE TRANSMITTED HIV ENVELOPE SIGNATURES' [patent_app_type] => utility [patent_app_number] => 12/450395 [patent_app_country] => US [patent_app_date] => 2008-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 3380 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0104/20100104596.pdf [firstpage_image] =>[orig_patent_app_number] => 12450395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5434927 [patent_doc_number] => 20090169513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-07-02 [patent_title] => 'Expression of virus entry inhibitors and recombinant AAV therefor' [patent_app_type] => utility [patent_app_number] => 12/079002 [patent_app_country] => US [patent_app_date] => 2008-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 8063 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0169/20090169513.pdf [firstpage_image] =>[orig_patent_app_number] => 12079002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4860623 [patent_doc_number] => 20080269473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2008-10-30 [patent_title] => 'Method' [patent_app_type] => utility [patent_app_number] => 12/077802 [patent_app_country] => US [patent_app_date] => 2008-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 60 [patent_no_of_words] => 24453 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0269/20080269473.pdf [firstpage_image] =>[orig_patent_app_number] => 12077802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5297335 [patent_doc_number] => 20090012261 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-01-08 [patent_title] => 'HLA Epitope Identification' [patent_app_type] => utility [patent_app_number] => 12/051543 [patent_app_country] => US [patent_app_date] => 2008-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 22421 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0012/20090012261.pdf [firstpage_image] =>[orig_patent_app_number] => 12051543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8113861 [patent_doc_number] => 08158131 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-04-17 [patent_title] => 'Recombinant dengue virus antigens comprising the C15 signal peptide, full-length PRM protein, and full-length E protein' [patent_app_type] => utility [patent_app_number] => 12/075097 [patent_app_country] => US [patent_app_date] => 2008-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 140033 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/158/08158131.pdf [firstpage_image] =>[orig_patent_app_number] => 12075097 [rel_patent_id] =>[rel_patent_doc_number] =>)